Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.36 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.34 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.34 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.32 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.32 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.32 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.32 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.32 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.32 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7573495 | 0.98 | HRH1 (0.38) | ALDH1A1KDM4ELMNAHRH1USP2 | |
| SCHEMBL15038753 | 0.74 | NOS1 (0.35) | USP2NOS1 | |
| SCHEMBL14753506 | 0.68 | INMT (0.43) | ALDH1A1LMNAUSP2 | |
| SCHEMBL14753505 | 0.68 | INMT (0.39) | ALDH1A1LMNAUSP2NOS1 | |
| SCHEMBL22106040 | 0.67 | INMT (0.47) | ALDH1A1LMNAUSP2 | |
| SCHEMBL22106038 | 0.67 | INMT (0.38) | USP2 | |
| SCHEMBL13117169 | 0.66 | SIGMAR1 (0.56) | ALDH1A1USP2ADRB1ADRB2PLD1 | |
| Acetic Acid SCHEMBL25355446 | 0.65 | INMT (0.40) | — | |
| SCHEMBL22106039 | 0.65 | USP2 (0.41) | ALDH1A1LMNAUSP2 | |
| SCHEMBL9987736 | 0.64 | LMNA (0.30) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147359-A1 | Intermediate compound for preparing guanidine and amidine derivatives | LUETTKE SVEN (DE) | 2002-10-10 | — | — | US | disclosed |
| US-6455700-B1 | THERAPY FOR NEUROKININ SENSITIVE DISEASE | BOEHRINGER INGELHEIM PHARMA KG. (DE) | 2002-09-24 | — | — | US | disclosed |
| US-20020133012-A1 | Process for preparing guanidine and amidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-19 | — | — | US | disclosed |
| US-6429328-B2 | REACTING AN AMIDE DERIVATIVE WITH A PIPERIDINE CONTAINING GUANIDINE GROUP TO PRODUCE THE PRODUCT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-06 | — | — | US | disclosed |
| US-20020010173-A1 | Processes and intermediate compounds for preparing guanidine and amidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-01-24 | — | — | US | disclosed |
| US-6277840-B1 | ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-08-21 | — | — | US | disclosed |
| US-6103719-A | NEUROKININ-A- OR NEUROKININ-B TACHNKININ ANTAGONISTIC PROPERTIES; SUBSTANCE P ANTAGONISM; RESPIRATORY, GASTROINTESTINAL, NERVOUS SYSTEM, SKIN DISORDERS; | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010173-A1 | Processes and intermediate compounds for preparing guanidine and amidine derivatives | CCKAR, NPY2R, CCKBR | HRH1 95/4885ADRB1 409/4885ADRB2 215/4885 |
| US-20020147359-A1 | Intermediate compound for preparing guanidine and amidine derivatives | NPY2R, CCKAR, NPY1R | HRH1 181/4885ADRB1 475/4885ADRB2 286/4885 |
| US-20020133012-A1 | Process for preparing guanidine and amidine derivatives | NPY2R, NPY1R, CCKAR | HRH1 113/4885ADRB1 287/4885ADRB2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.